866-997-4948(US-Canada Toll Free)

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 69 Pages

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Venous Leg Ulcers (Crural ulcer), West Nile Virus Infections, Wounds and Zika Virus Infections.

Furthermore, this report also reviewsalso reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
Hemispherx Biopharma Inc
Innate Pharma SA
Johnson & Johnson
MultiCell Technologies Inc
Oncovir Inc
RMB-Research GmbH
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNTO-3157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CU-CPT4a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCT-465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-0202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Statmicoll - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
May 15, 2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
Mar 06, 2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017
Feb 09, 2017: hVIVO announces data from two Phase IIa clinical studies to further profile PrEP Biopharms PrEP-001 as a potential prophylactic against the common cold
Jan 26, 2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe
Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
Oct 19, 2016: Hemispherx Biopharma Announces Completion of Ampligen Manufacturing Technology Transfer Milestone
Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHIs 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
Jul 25, 2016: Hemispherx Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe
Jun 14, 2016: hVIVO - Favourable results for PrEP Biopharms Flu Study
Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Expert Review of Clinical Pharmacology
Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Hemispherx Biopharma Inc, H1 2017
Pipeline by Innate Pharma SA, H1 2017
Pipeline by Johnson & Johnson, H1 2017
Pipeline by MultiCell Technologies Inc, H1 2017
Pipeline by Oncovir Inc, H1 2017
Pipeline by RMB-Research GmbH, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1), H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *